A phase II trial of topotecan in patients with previously untreated pancreatic cancer

Anti-Cancer Drugs

Volumn 7, Issue 4, 1996, Pages 410-414

  O'Reilly, Seamus ^a   Donehower, Ross C ^a   Rowinsky, Eric K ^a   Ord, Sarah ^a   Grochow, Louise B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Pancreatic cancer; Topotecan

Indexed keywords

CAMPTOTHECIN DERIVATIVE; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG INFUSION; FATIGUE; FEMALE; FEVER; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TOPOTECAN;

EID: 0029934111     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199606000-00006     Document Type: Article

References (31)

1. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J Clin 1995; 45: 8-30.
2. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Eng J Med 1992; 326: 455-65.
3. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6 19-28.
4. Williamson RCN. Pancreatic cancer: the greatest oncological challenge. Br Med J 1988; 296: 445-6.
5. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer Results of a controlled, prospective randomized multicenter trial. Br Med J 1980; 281: 1589-91.
6. Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-5.
7. Pantazis P. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments. Clin Cancer Res 1995; 1: 1235-44.
8. Kaufman SH. Additional members of the rat liver lamin polypeptide family. J Biol Chem 1989; 264: 13946-55.
9. Duget M, Lavenot C, Harper F, et al. DNA topoisomerases from rat liver: physiological variations. Nucleic Acids Res 1983; 11: 1059-75.
10. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer. Science 1989; 246: 1046-8.
11. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994 54: 1431-9.
12. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic - Thirteenth Bruce F Cain Memorial Award Lecture. Cancer Res 1995; 55 753-60.
13. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufman SH. The current status of the camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-91.
14. Kingsbury WD, Boehm JC, Jakes DR, et al. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and anti-tumor activity J Med Chem 1991; 34: 98-107.
15. Rowinsky E, Grochow L, Hendricks C, et al. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992; 10 647-56.
16. Recondo G, Abbruzzese J, Newman B, et al. Phase I and pharmacokinetic trial of topotecan on a weekly 24hr infusion schedule. Proc Am Ass Cancer Res 1991; 32: 206
17. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacologic study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempts at dose intensification using recombinant granulocyte colony stimulating factors J Natl Cancer Inst 1993; 85: 1499-507.
18. van Warmerdam LJC, Verweij J. Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks Cancer Chemother Pharmacol 1995; 35: 237-45.
19. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute 1988.
20. Gehan EA. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-53.
21. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Statist Ass 1958; 53: 457-81.
22. Sugarman SM, Pazdur R, Daughtery K, et al. A phase II trial of topotecan for the treatment of unresectable pancreatic cancer Proc Am Soc Clin Oncol 1994; 13 224.
23. Wagener DJTh, Verdonk HER, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6: 129-32.
24. Sakata Y, Wakui A, Nakao I, et al. A late phase II study of irinotecan in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1993; 12: 211.
25. Hochster H, Liebes L, Speyer J, et al Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well tolerated regimen. J Clin Oncol 1994;12: 53-9.
26. O'Reilly S, Rowinsky EK, Slichenmyer W. et al Phase I and pharmacologic study of topotecan in patients with abnormal liver function. J Natl Cancer Inst, in press.
27. Seymour AB, Hruban RH, Redston M, et al. Allelotype of pancreatic cancer. Cancer Res 1994; 54: 2761-4.
28. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention Cancer Res 1995; 55: 1856-62.
29. Hruban RH, van Mansfield ADM, Offerhaus GJA, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-54.
30. Aoki K, Yoshida T, Sugimara T, Masaaki T. Liposome mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810-6.
31. Blaskovich M, Qian Y, Lerner E, et al. Ras CAAX peptidomimetics inhibit tumor growth in nude mice. Proc Am Ass Cancer Res 1995; 36: 432.